Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

[1]  A. Idbaih,et al.  Identification, validation and biological characterization of novel Glioblastoma Tumour Microenvironment subtypes: Implications for precision immunotherapy. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  T. Todo,et al.  Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial , 2022, Nature Medicine.

[3]  G. Dharmadhikari,et al.  Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. , 2022, The New England journal of medicine.

[4]  R. McLendon,et al.  Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy , 2021, Nature communications.

[5]  P. Wen,et al.  Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma , 2020, Clinical Cancer Research.

[6]  M. Weller,et al.  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma , 2020, JAMA oncology.

[7]  S. Sleijfer,et al.  Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy , 2020, Neuro-oncology advances.

[8]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[9]  Daniel J. Freeman,et al.  Optimizing oncolytic virotherapy in cancer treatment , 2019, Nature Reviews Drug Discovery.

[10]  R. Rabadán,et al.  Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma , 2019, Nature Medicine.

[11]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[12]  P. Wen,et al.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma , 2018, Nature Medicine.

[13]  E. Chiocca,et al.  Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual? , 2018, Neuro-oncology.

[14]  M. Atkins,et al.  Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain , 2018, The New England journal of medicine.

[15]  William T. Harrison,et al.  Recurrent Glioblastoma Treated with Recombinant Poliovirus , 2018, The New England journal of medicine.

[16]  K. Aldape,et al.  Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[18]  Michael E. Lassman,et al.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.

[19]  Susan M. Chang,et al.  Response Assessment in Neuro-Oncology Clinical Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Benjamin M. Ellingson,et al.  Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials , 2017, Neurotherapeutics.

[21]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[22]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[23]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[24]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[25]  R. Vernhout,et al.  Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. , 2014, The Lancet. Oncology.

[26]  A. Kleijn,et al.  The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity , 2014, PloS one.

[27]  P. Gutin,et al.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. , 2012, European journal of cancer.

[28]  T. Yeatman,et al.  Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. , 2011, The American journal of pathology.

[29]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[31]  G. Fuller,et al.  Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. , 2003, Journal of the National Cancer Institute.

[32]  J R Anderson,et al.  Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[34]  J. Lunceford,et al.  IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade , 2017 .